Advertisement


Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Platinum-Based Chemotherapy vs Capecitabine

2021 ASCO Annual Meeting

Advertisement

Ingrid A. Mayer, MD, of Vanderbilt University Medical Center, discusses phase III results from a trial that showed patients with triple-negative breast cancer who had residual invasive disease after neoadjuvant chemotherapy had lower-than-expected invasive disease–free survival, regardless of study treatment with platinum-based chemotherapy or capecitabine (Abstract 605).



Related Videos

Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Abiraterone Acetate, Prednisone, and Radiotherapy in Metastatic Disease

Karim Fizazi, MD, PhD, of Institut Gustave Roussy, discusses first results from the phase III PEACE1 trial, which showed that abiraterone plus androgen-deprivation therapy and docetaxel improves radiographic progression-free survival in men with de novo metastatic prostate cancer (Abstract 5000).

Lung Cancer
Issues in Oncology

Debora S. Bruno, MD, on NSCLC: Racial Disparities in Biomarker Testing and Clinical Trial Enrollment

Debora S. Bruno, MD, of Seidman Cancer Center at Cleveland Medical Center, discusses study findings that show Black patients with advanced or metastatic non–small cell lung cancer tend to be less likely to undergo biomarker testing or to be treated in clinical trials than White patients. Recommended broad-based testing, says Dr. Bruno, may help ensure equal access to quality care and clinical trials (Abstract 9005).

Leukemia
Immunotherapy

Bijal D. Shah, MD, on CLL: CAR T-Cell Therapy With Brexucabtagene Autoleucel

Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses phase II results of the ZUMA-3 study, which evaluated brexucabtagene autoleucel (KTE-X19), an anti-CD19 CAR T-cell therapy, in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (Abstract 7002).

Breast Cancer

Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy

Priya Rastogi, MD, of the University of Pittsburgh, discusses results from the NRG Oncology/NSABP B-42 trial, which evaluated the utility of the 70-gene MammaPrint assay in predicting the benefit of extended letrozole therapy in patients who had completed 5 years of adjuvant endocrine therapy (Abstract 502).

Lymphoma

Brian K. Link, MD, on Mantle Cell Lymphoma: Expert Perspective on Treatments Now and Those to Come

Brian K. Link, MD, of the University of Iowa Carver College of Medicine, reviews three abstracts on state-of-the-art therapies for mantle cell lymphoma: bendamustine, rituximab, lenalidomide and bortezomib; treatment patterns and outcomes for previously untreated patients; and venetoclax, lenalidomide, and rituximab in newly diagnosed disease (Abstracts 7503, 7504, and 7505).

Advertisement

Advertisement



Advertisement